Global Business Report series • USA Life Sciences 2023

Published in: Global Business Reports - United States Life Sciences 2023

In many ways, 2022 was a turning point for the U.S. life sciences industry. After having experienced a record number of deals, IPOs, and drug approvals in 2020 and 2021, the past year was marked by post-pandemic recovery, macroeconomic shockwaves, and regulatory changes that industry leaders fear could cool the industry’s expansion going forward.

Yet, positive signs point toward another year of growth for the life sciences industry.

Premier is a leading healthcare improvement company, uniting an alliance of more than 4,400 US hospitals and health systems and approximately 250,000 other providers and organizations to transform healthcare. Premier has integrated data and analytics, collaboratives, supply chain solutions, consulting, and other services available to healthcare organizations, enabling better care and outcomes at a lower cost. In July 2022, Premier’s Performance Services business rebranded as PINC AI™.

The PINC AI Applied Sciences team works on prospective, retrospective and improvement science research as well as clinical trials to help close gaps in care, accelerate evidence into practice and implement workflow solutions to hardwire sustainable change.

PINC AI™ data combined with natural language processing (NLP) technology is well suited for uncovering details in unstructured notes that can help identify which risk factors and clinical signs and symptoms are most predictive of subsequent disease development.

“A tangible example is a study we did in the New York market. We had a hypothesis that people were getting lung scans because of Covid-19. Based on the radiology report, many people could have incidental pulmonary nodules (IPN), which could be an indication of early-stage lung cancer,” stated Denise Juliano, group vice president, life sciences of Premier Inc. “By applying NLP technology, we were able to identify patients with IPNs and flag them for intervention before potential lung cancer progression.”

Click here for access to full report.